Skip to main content

Biogen is cutting 2022 expenses for Q2, profit forecast is raised

Biogen's second quarter expectations were soundly exceeded. Biogen was able to do this by slashing spending on the controversial drug Aduhelm.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.